View : 248 Download: 0
Serum ceruloplasmin and striatal dopamine transporter density in Parkinson disease: Comparison with 123I-FP-CIT spect
- Serum ceruloplasmin and striatal dopamine transporter density in Parkinson disease: Comparison with 123I-FP-CIT spect
- Song Y.S.; Kim J.-M.; Kim K.J.; Yun J.Y.; Kim S.E.
- Ewha Authors
- SCOPUS Author ID
- Issue Date
- Journal Title
- Clinical Nuclear Medicine
- Clinical Nuclear Medicine vol. 42, no. 9, pp. 675 - 679
- 123 I-FP-CIT SPECT; ceruloplasmin; dopamine; Parkinson disease
- Lippincott Williams and Wilkins
- SCIE; SCOPUS
- Document Type
- Purpose In patients with Parkinson disease (PD), decreased serum ceruloplasmin levels have been observed. This study investigated a correlation between serum ceruloplasmin - along with its related serum markers -and striatal presynaptic dopaminergic denervation measured with 123 I-FP-CIT SPECT. Methods We analyzed a total of 141 de novo patients divided into 2 groups: the PD group (107 patients with PD) and the disease control group (34 patients with vascular pseudoparkinsonism, essential tremor, or drug-induced parkinsonism). Serum ceruloplasmin and related serum markers, such as copper, iron, total iron-binding capacity, and ferritin, were measured. Specific binding ratios of the striatum, caudate nucleus, putamen, and posterior putamen were obtained by 123 I-FP-CIT SPECT. Results There was no difference in the serum markers, except for ceruloplasmin, between the 2 groups. Ceruloplasmin level was significantly lower in PD patients with longer symptom duration (>2 years) than in the disease control group (21.4 ± 3.4 vs 24.0 ± 3.8, P = 0.03). Serum ceruloplasmin had a significant correlation with specific binding ratios of the striatum, caudate nucleus, and putamen in a subgroup with longer symptom duration (P = 0.01, P = 0.02, P = 0.02, respectively, for the subgroup with symptom duration >1 year, and P < 0.01, P < 0.01, P = 0.04, respectively, for the subgroup with symptom duration >2 years). Conclusions Decrease in serum ceruloplasmin had a positive correlation with a decrease in dopamine transporter density in PD patients with symptom duration of more than 1 year. © 2017 Wolters Kluwer Health, Inc. All rights reserved.
- Appears in Collections:
- 의료원 > 의료원 > Journal papers
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.